These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 12911582

  • 1. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?
    Brown SA, Eldridge A, Collins PW, Bowen DJ.
    J Thromb Haemost; 2003 Aug; 1(8):1714-7. PubMed ID: 12911582
    [Abstract] [Full Text] [Related]

  • 2. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, Jenkins PV, van Mourik JA.
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [Abstract] [Full Text] [Related]

  • 3. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
    Callan MB, Giger U, Catalfamo JL.
    Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A, Greist A, Di Paola J, Winay J, Roberson C, Heiman M, Herbert S, Parameswaran R, Shapiro A.
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [Abstract] [Full Text] [Related]

  • 6. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.
    Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP.
    Br J Haematol; 2000 Jun; 109(4):865-9. PubMed ID: 10929043
    [Abstract] [Full Text] [Related]

  • 7. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
    Sztukowska M, Gallinaro L, Cattini MG, Pontara E, Sartorello F, Daidone V, Padrini R, Pagnan A, Casonato A.
    Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R.
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ, Casanova R.
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.